Striatal glutamatergic mechanisms and extrapyramidal movement disorders

Neurotoxicity Research

Volumn 5, Issue 1-2, 2003, Pages 139-145

  Chase, Thomas N ^a   Bibbiani, Francesco ^a   Oh, Justin D ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

AMPA; Huntington disease; Lonotropic receptor; LTP, Medium spiny neuron; NMDA

Indexed keywords

DOPAMINE; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR;

ANIMAL; CELL TRANSPLANTATION; DRUG EFFECT; HUMAN; METABOLISM; MOTOR DYSFUNCTION; NERVE CELL; PARKINSON DISEASE; PHYSIOLOGY; REVIEW; TRANSPLANTATION;

ANIMALS; CELL TRANSPLANTATION; DOPAMINE; HUMANS; MOVEMENT DISORDERS; NERVE GROWTH FACTORS; NEURONS; PARKINSON DISEASE; RECEPTORS, NERVE GROWTH FACTOR;

EID: 0642345900     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033378     Document Type: Article

References (105)

1. Ahlskog JE and MD Muenter (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16, 448-458.
2. Ahn S, DD Ginty and DJ Linden (1999) A late phase of cerebellar long-term depression requires activation of CaMKIV and CREB. Neuron 23, 559-568.
3. Andersson M, A Hilbertson and MA Cenci (1999) Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6, 461-474.
4. Anglade P, A Mouatt-Prigent, Y Agid and E Hirsch (1996) Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration 5, 121-128.
5. Bartsch D, A Casadio, KA Karl, P Serodio and ER Kandel (1998) CREB1 encodes a nuclear activator, a repressor, and a cytoplasmic modulator that form a regulatory unit critical for long-term facilitation. Cell 95, 211-223.
6. Bayer KU, P De Koninck, AS Leonard, JW Hell and H Schulman (2001) Interaction with the NMDA receptor locks CaMKII in an active conformation. Nature 411, 801-805.
7. Bibb JA, JS Chen, JR Taylor, P Svenningsson, A Nishi, GL Snyder, Z Yan, ZK Sagawa, CC Ouimet, AC Nairn, EJ Nestler and P Greengard (2001) Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature 410, 376-380.
8. Blanchet PJ, LV Metman, MM Mouradian and TN Chase (1996) Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov. Disord. 11, 580-581.
9. Blanchet PJ, SM Papa, LV Metman, MM Mouradian and TN Chase (1997) Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci. Biobehav. Rev. 21, 447-453.
10. Blanchet PJ, S Konitsiotis and TN Chase (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. 13, 798-802.
11. Blanchet PJ, S Konitsiotis, N Whitmore, R Woodward and TN Chase (1999) Different effects of subunit specific NMDA antagonists in parkinsonian monkeys. J. Pharmacol. Exp. Ther. 290, 1034-1040.
12. Cain DP (1997) LTP, NMDA, genes and learning. Curr. Opin. Neurobiol. 7, 235-242.
13. Calabresi P, P Giacomini, D Centonze and G Bernardi (2000) Levodopa-induced dyskinesia: A pathological form of striatal synaptic plasticity? Ann Neurol. 47(4 Suppl 1), S60-S8.
14. Cenci MA, CS Lee and A Björklund (1998) L-Dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10, 2694-2706.
15. Cenci MA, A Tranberg, M Andersson and A Hilbertson (1999) Changes in the regional and compartmental distribution of FodB-and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 94, 515-527.
16. Centonze D, B Picconi, P Gubellini, G Bernardi and P Calabresi (2001) Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur. J. Neurosci. 6, 1071-1077.
17. Cepeda C and MS Levine (1998) Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev. Neurosci. 20, 1-18
18. Cervo L and R Samanin (1996) Effects of dopaminergic and glutamatergic receptor antagonists on the establishment and expression of conditioned locomotion to cocaine in rats. Brain Res. 731, 31-38.
19. Chase TN and JD Oh (2000a) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23, S86-S91.
20. Chase TN and JD Oh (2000b) Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann. Neurol. 4(Suppl 1), S122-S129.
21. Chase TN, JD Oh and S Konitsiotis (2000) Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol. 247 (Suppl 2), 36-42.
22. Chen Q and A Reiner (1996) Cellular distribution of the NMDA receptor NR2A/2B subunits in the rat striatum. Brain Res. 743, 346-352.
23. Clarke CE, MA Sambrook, IJ Mitchell and ARH Crossman (1987) Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Neurol. Sci. 78, 273-280.
24. Crump FT, KS Dillman and AM Craig (2001) cAMP-dependent protein kinase mediates activity-regulated synaptic targeting of NMDA receptors. J. Neurosci. 21, 5079-5088.
25. Danysz W, CG Parons, J Kornhuber, WJ Schmidt and G Quack (1997) Amino-adamentanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci. Biobehav. Rev. 21, 455-468.
26. 1 receptors regulate the phosphorylation of CREB and the induction of c-fos in striatal neurons in primary culture. Synapse 25, 227-233.
27. Del Dotto P, N Pavese, G Gambaccini, S Bernardini, LV Metman, TN Chase and U Bonuccelli (2001) Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study. Mov. Disord. 16, 515-520.
28. 1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J. Neurosci. 21, 5546-5558.
29. Engber TM, Z Susel, S Kuo, CR Gerfen and TN Chase (1991) Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. 552, 113-118.
30. 2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res. 581, 261-268.
31. Engber TM, SM Papa, RC Boldry and TN Chase (1994) NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5, 2586-2588.
32. Freund TF, JF Powell and AD Smith (1984) Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience 4, 1189-1215.
33. Gerfen CR (1992) The neostriatal mosiac: Multiple levels of compartmental organization in the basal ganglia. Ann. Rev. Neurosci. 15, 285-320.
34. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432.
35. Ginty DD (1997) Calcium regulation of gene expression: Isn't that spatial? Neuron 2, 183-186.
36. Gomez-Mancilla B and PJ Bedard (1993) Effect of nondopaminergic drugs on L dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol. 16, 418-427.
37. Gonzalez GA, P Menzel, J Leonard, WH Fischer and MR Montminy (1991) Characterization of motifs which are critical for activity of the cyclic AMP-responsive transcription factor CREB. Mol. Cell. Biol. 11, 1306-1312.
38. Goto S, A Hirano A and RR Rojas-Corona (1989) Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders. Acta Neuropathol. (Berl.) 78, 543-550.
39. Graybiel AM (1998) The basal ganglia and chunking of action repertoires. Neurobiol. Learn. Mem. 1, 119-136.
40. Graybiel AM (2000) The basal ganglia. Curr. Biol. 14, R509-R511.
41. Greengard P, PB Allen and AC Nairn (1999) Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23, 435-447.
42. Grosshans DR and MD Browning (2001) Protein kinase C activation induces tyrosine phosphorylation of the NR2A and NR2B subunits of the NMDA receptor. J. Neurochem. 76, 737-744.
43. Gurd JW (1997) Protein tyrosine phosphorylation: Implications for synaptic function. Neurochem. Int. 31, 635-649.
44. Hollmann M and S Heinemann (1994) Cloned glutamate receptors. Ann. Rev. Neurosci. 17, 31-108.
45. Hope BT, HE Nye, MB Kelz, DW Self, MJ Ladarola, Y Nakabeppu, RS Duman and EJ Nestlet (1994) Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 13, 1235-1244.
46. Hornykiewicz O (1998) Biochemical aspects of Parkinson's disease. Neurology 51, S2-S9.
47. Hu SC, J Chrivia and A Ghosh (1999) Regulation of CBP-mediated transcription by neuronal calcium signaling. Neuron 22, 799-808.
48. Huang EP and CF Stevens (1998) The matter of mind: Molecular control of memory. Essays Biochem. 33, 165-178.
49. Impey S, DM Smith, K Obrietan, R Donahue, C Wade and DR Storm (1998) Stimulation of cAMP response element (CRE)-mediated transcription during contextual learning. Nature Neurosci. 1, 595-601.
50. Karcz-Kubicha M, G Quack and W Danysz (1998) Amantadine attenuates response alterations resulting from repetitive L-DOPA treatment in rats. J. Neural Transm. 105, 1229-1236
51. Kelz MB, JS Chen, WA Carlezon, K Whisler, L Gilden, AM Beckmann, C Steffen, YJ Zhang, L Marotti, DW Self, T Tkatch, G Baranauskas, DJ Surmeier, RL Neve, RS Duman, MR Picciotto and EJ Nestler (1999) Expression of the transcriptional factor ΔFosB in the brain controls sensitivity to cocaine. Nature 401, 272-276.
52. Khan SM, TS Smith and JP Bennett (1999) Effects of single and multiple treatments with L-dihydroxyphenylalanine (L-DOPA) on dopamine receptor-G protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal lesions. J. Neurosci. Res. 55, 55-71.
53. Klockgether T, L Turski, T Honore, Z Zhang, DM Gash, R Kurlan and JT Greenamyre (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30, 717-723.
54. Konitsiotis S, PJ Blanchet, L Verhagen, E Lamers and TN Chase (2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 8, 1589-1595.
55. Kotter R (1994) Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog. Neurobiol. 44, 163-196.
56. Lan JY, VA Skeberdis, T Jover, SY Grooms, Y Lin, RC Araneda, X Zheng, MVL Bennett and RS Zukin (2001) Protein kinase C modulates NMDA receptor trafficking and gating. Nature Neurosci. 4, 382-390.
57. Lew J, Q Huang, Q Zhong, R Winkfein, R Aebersold, T Hunt and J Wang (1994) A brain-specific activator of cyclin-dependent kinase 5. Nature 271, 423-426.
58. Liao GY, DA Wagner, MH Hsu and JP Leonard (2001) Evidence for direct protein kinase-C mediated modulation of N-methyl-D-aspartate receptor current. Mol. Pharmacol. 59, 960-964.
59. Luquin MR, JA Obesbo, J Laguma, J Guillen and JM Martinez-Lage (1993) the AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur. J. Pharmaol. 235, 297-300.
60. Marin C, S Papa, TM Engber, M Bonastre, E Tolosa and TN Chase (1996) MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 736, 202-205.
61. Marin C, A Jimenez, M Bonastre, TN Chase and E Tolosa (2000) Non-NMDA receptor-mediated mechanisms in levodopa-induced motor response alterations in parkinsonian rats. Synapse 36, 267-274.
62. Mayer ML and GL Westbrook (1987) The physiology of excitatory amino acids in the vertebrate central nervous system. Prog. Neurobiol. 3, 197-276.
63. McDonald BJ, HJ Chung and RL Huganir (2001) Identification of protein kinase C phosphorylation sites within the AMPA. Neuropharmacology 6, 672-679.
64. Menegoz M, LF Lau, D Herve, RL Huganir and JA Girault (1995) Tyrosine phosphorylation of NMDA receptor in rat striatum: Effects of 6-OH-dopamine lesions. Neuroreport 7, 125-128.
65. Merello M, MI Nouzeilles, A Cammarota and R Leiguarda (1999) Effect of memantine (NMDA antagonist) on Parkinson's disease: A double blind crossover randomized study. Clin. Neuropharmacol. 22, 273-276.
66. Meshul CK and C Allen (2000) Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion. Synapse 2, 129-142.
67. Metman LV, PJ Blancet, P van den Munckhof, P Del Dotto, R Natte and TN Chase (1998a) A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov. Disord. 13, 414-417.
68. Metman LV, PD Dotto, P van den Munckhof, J Fang, MM Mouradian and TN Chase (1998b) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50, 1323-1329.
69. Metman LV, PD Dotto, R Natte, P van den Munckhof and TN Chase (1998c) Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 51, 203-206.
70. Mitchell IJ and CB Carroll (1997) Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: Potential mechanisms of action. Neurosci. Biobehav. Rev. 21, 469-475.
71. Mouradian MM, IJ Heuser, F Baronti and TN Chase (1990) Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann. Neurol. 27, 18-23.
72. Nicoll RA and RC Malenka (1995) Contrasting properties of two forms of long-term potentiation in the hippocampus. Nature 377, 115-118.
73. Nishi A, JA Bibb, GL Snyder, H Higashi, AC Nairn and P Greengard (2000) Amplification of dopaminergic signaling by a positive feedback loop. Proc. Natl. Acad. Sci. USA 97, 12840-12845.
74. Oh JD, PD Dotto and TN Chase (1997) Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci. Lett. 228, 5-8.
75. Oh JD, D Russell CL Vaughan and TN Chase (1998) Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: Effect of dopaminergic denervation and levodopa administration. Brain Res. 813, 150-159.
76. Oh JD, CL Vaughan and TN Chase (1999), Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res. 821, 433-442.
77. Ozawa S, H Kamiya and K Tsuzuki (1998) Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. 54, 581-618.
78. Papa SM and TN Chase (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39, 574-578.
79. Papa SM, TM Engber AM Kask and TN Chase (1994) Motor fluctuations in levodopa treated parkinsonian rats: Relation to lesion extent and treatment duration. Brain Res. 662, 69-74.
80. Papa SM, RC Boldry, TM Engber, AM Kask and TN Chase (1995) Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 701, 13-18.
81. Parent A and F Cicchetti (1998) The current model of basal ganglia organization under scrutiny. Mov. Disord. 2, 199-202.
82. Parent A, MC Asselin and PY Cote (1996) Dopaminergic regulation of peptide gene expression in the striatum of normal and parkinsonian monkeys. Adv. Neurol. 69, 73-77.
83. Pietruck C, G-X Xie, M Sharma, T Meuser and PP Palmer (1999) Multiple splice patterns of cyclic AMP response element-binding protein mRNA in the central nervous system of the rat. Mol. Brain Res. 69, 286-289.
84. Pittenger C and E Kandel (1998) A genetic switch for long-term memory. Life Sci. 321, 91-96.
85. Quinn PG (1993) Distinct activation domains within cAMP response element-binding protein (CREB) mediate basal and cAMP-stimulated transcription. J. Biol. Chem. 268, 16999-17009.
86. Reiner A, R Albin, KD Anderson, CJ D'Amato, JB Penney and AB Young (1988) Differential loss of striatal projection neurons in Huntington's disease. Proc. Natl. Acad. Sci. USA 85, 5733-5737.
87. Sachdev PS (2000) The current status of tardive dyskinesia. Aust. NZ J. Psychiatry 3, 355-369.
88. Schultz W (1994) Behavior-related activity of primate dopamine neurons. Rev. Neurol. 150, 634-639.
89. Sheng M, MA Thompson and ME Greenberg (1991) CREB, a Ca(2+) regulated transcription factor phosphorylated by calmodulin-dependent kinase. Science 252, 1427-1430.
90. Silva AJ, JH Kogan, PW Frankland and S Kida (1998) CREB and memory. Ann. Rev. Neurosci. 21, 127-148.
91. Smith Y, BD Bennett, JP Bolam, A Parent and AF Sadikot (1994) Synaptic relationships between dopaminergic afferents and cortical or thalamic input in the sensorimotor territory of the striatum in monkey. J. Comp. Neurol. 1, 1-19.
92. Snyder GL, PB Allen, AA Fienberg, CG Valle, RL Huganir, AC Nairn and P Greengard (2000) Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo. J. Neurosci. 12, 4480-4488.
93. 1-receptor/PKA/DARPP-32/ PPI pathway regulates AMPA receptor phosphorylation and conductance in the neostriatum. Brit. J. Pharmacol. 133, 268.
94. Sommer B, K Keinanen, TA Verdoorn, W Wisden, N Burnashev, A Herb, M Kohler, T Takagi, B Sakmann and PH Seeburg (1990) flip and flop: A cell-specific functional switch in glutamate-operated channels of the CNS. Science 249, 1580-1585.
95. Suen PC, K Wu, JL Xu, SY Lin, ES Levine and IB Black (1998) NMDA receptor subunits in the postsynaptic density of rat brain: Expression and phosphorylation by endogenous protein kinases. Mol. Brain Res. 59, 215-228.
96. Sun Y, A Savanenin, PH Reddy and YF Liu (2001) Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 27, 24713-24718.
97. Swope SL, SI Moss, LA Raymond and RL Huganir (1999) Regulation of ligand-gated ion channels by protein phosphorylation. Adv. Second Messenger Phosphoprot. Res. 33, 49-78.
98. Tingley WG, MD Ehlers, K Kameyama, C Doherty, JB Ptak, CT Riley and RL Huganir (1997) Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site specific antibodies. J. Biol. Chem. 72, 5157-5166.
99. Ulas J and C Cotman (1996) Dopaminergic denervation of striatum results in elevated expression of NR2A subunit. J. Neuroreport 7, 1789-1793.
100. Verhagen L, M Morris, C Farmer, M Gillespie, J Wuu and TN Chase (2001) A double-blind placebo-controlled crossover study of the effect of amantadine on chorea in Huntington's disease. Neurology 56 (Suppl 3), A386.
101. Vonsattel JP and M DiFiglia (1998) Huntington disease. J. Neuropathol. Exp. Neurol. 5, 369-384.
102. Westbrook GL (1994) Glutamate receptor update. Curr. Opin. Neurobiol. 3, 337-346.
103. Wirshing WC (2001) Movement disorders associated with neuroleptic treatment. J. Clin. Psychiatry 62 (Suppl 21), 15-18.
104. Wollmuth LP, T Kuner, PH Seeburg and B Sakmann (1996) Differential contribution of the NR1- and NR2A-subunits to the selectivity filter of recombinant NMDA receptor channels. J. Physiol. (Lond.) 491, 779-797.
105. Yu XM, R Askalan, GJ Keil II and MW Salter (1997) NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science 275, 674-678.